JP2004527206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004527206A5 JP2004527206A5 JP2001582388A JP2001582388A JP2004527206A5 JP 2004527206 A5 JP2004527206 A5 JP 2004527206A5 JP 2001582388 A JP2001582388 A JP 2001582388A JP 2001582388 A JP2001582388 A JP 2001582388A JP 2004527206 A5 JP2004527206 A5 JP 2004527206A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- group
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56878300A | 2000-05-10 | 2000-05-10 | |
| PCT/US2001/015043 WO2001085789A2 (en) | 2000-05-10 | 2001-05-09 | Extracellular domain of ryk protein for regulating angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004527206A JP2004527206A (ja) | 2004-09-09 |
| JP2004527206A5 true JP2004527206A5 (enExample) | 2008-06-26 |
Family
ID=24272718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001582388A Pending JP2004527206A (ja) | 2000-05-10 | 2001-05-09 | Ｒｙｋタンパク質を使用する新脈管形成の調節方法 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1287121A2 (enExample) |
| JP (1) | JP2004527206A (enExample) |
| AR (1) | AR028424A1 (enExample) |
| AU (1) | AU2001261343A1 (enExample) |
| CA (1) | CA2408349A1 (enExample) |
| CO (1) | CO5300464A1 (enExample) |
| DO (1) | DOP2001000164A (enExample) |
| EC (1) | ECSP014068A (enExample) |
| GT (1) | GT200100079A (enExample) |
| PE (1) | PE20011218A1 (enExample) |
| SV (1) | SV2002000442A (enExample) |
| UY (1) | UY26696A1 (enExample) |
| WO (1) | WO2001085789A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005516608A (ja) * | 2002-02-06 | 2005-06-09 | デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング | エネルギー恒常性の調節に関与するキナーゼ |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| MA40354A (fr) | 2014-07-18 | 2017-05-24 | Sanofi Sa | Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer |
| US20250027945A1 (en) * | 2021-08-18 | 2025-01-23 | The Regents Of The University Of California | Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107472A (en) * | 1992-05-11 | 2000-08-22 | Ludwig Institute For Cancer Research | Receptor-type tyrosine kinase-like molecules |
| NZ300808A (en) * | 1994-12-23 | 1999-04-29 | Ludwig Inst Cancer Res | A method of detecting a ligand capable of binding the receptor protein nyk |
| WO1999064589A1 (en) * | 1998-06-11 | 1999-12-16 | Astrazeneca Ab | Human receptor tyrosine kinase |
| EP1126869B1 (en) * | 1998-10-28 | 2008-09-03 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using the trk receptor ligands bdnf, nt-3 and nt-4 |
-
2001
- 2001-05-07 GT GT200100079A patent/GT200100079A/es unknown
- 2001-05-07 AR ARP010102149A patent/AR028424A1/es not_active Application Discontinuation
- 2001-05-08 UY UY26696A patent/UY26696A1/es not_active Application Discontinuation
- 2001-05-09 JP JP2001582388A patent/JP2004527206A/ja active Pending
- 2001-05-09 WO PCT/US2001/015043 patent/WO2001085789A2/en not_active Ceased
- 2001-05-09 CO CO01036462A patent/CO5300464A1/es unknown
- 2001-05-09 AU AU2001261343A patent/AU2001261343A1/en not_active Abandoned
- 2001-05-09 CA CA002408349A patent/CA2408349A1/en not_active Abandoned
- 2001-05-09 EC EC2001004068A patent/ECSP014068A/es unknown
- 2001-05-09 SV SV2001000442A patent/SV2002000442A/es not_active Application Discontinuation
- 2001-05-09 EP EP01935233A patent/EP1287121A2/en not_active Withdrawn
- 2001-05-10 DO DO2001000164A patent/DOP2001000164A/es unknown
- 2001-05-10 PE PE2001000417A patent/PE20011218A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4881433B2 (ja) | 治療薬の薬物動態の調整 | |
| JP2002503641A5 (enExample) | ||
| JP2004501162A5 (enExample) | ||
| JP2004511201A5 (enExample) | ||
| JP2009542696A5 (enExample) | ||
| JP2003527079A5 (enExample) | ||
| JP2009537143A5 (enExample) | ||
| WO2006005707A3 (en) | Method for preventing and treating alzheimer´s disease | |
| JP2008529558A5 (enExample) | ||
| WO2004062556A3 (en) | Methods for preventing and treating alzheimer’s disease (ad) | |
| JP2002542827A5 (enExample) | ||
| JP2005237328A5 (enExample) | ||
| JP2003510050A5 (enExample) | ||
| CA2329800A1 (en) | Protein formulations | |
| CA2470731A1 (en) | Corticotropin releasing factor 2 receptor agonists | |
| EP1600441A3 (en) | Novel crystalline form of lercanidipin hydrochloride and processes for its preparation | |
| UA91820C2 (ru) | Терапевтическое применение вариантов хемокинов | |
| WO1999014345A3 (de) | Arzneimittel zur therapie einer manifesten lyme-borreliose | |
| JP2004527206A5 (enExample) | ||
| JP2002533115A5 (enExample) | ||
| WO2002004487A3 (de) | Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen | |
| JP2005179268A5 (enExample) | ||
| JP2007536910A5 (enExample) | ||
| JP2001294524A5 (enExample) | ||
| WO2002013845A3 (en) | Inflammation related g-protein coupled receptor |